Presseportal.de - Eli Lilly and Company http://www.presseportal.de/pm/17573/eli_lilly_and_company/ Presseportal.de: Eli Lilly and Company (Digitale Pressemappe) de-de news aktuell GmbH redaktion@presseportal.de Sun, 14 Mar 2010 00:00:01 +0100 Tue, 05 Jan 2010 15:47:00 +0200 6 http://www.presseportal.de/images/logo_napresseportal.gif Presseportal.de http://www.presseportal.de/pm/17573/eli_lilly_and_company/ New Analysis Showed Efient(R) Cost-Effective Compared with Clopidogrel for Patients with Acute Coronary Syndromes Undergoing PCI http://www.presseportal.de/pm/17573/1539779/eli_lilly_and_company/rss Eli Lilly and Company: Tokyo and Indianapolis (ots/PRNewswire) - Results from a health economic substudy of the TRITON-TIMI 38 clinical trial showed that among patients with acute coronary syndrome (ACS) managed with percutaneous coronary intervention ... Eli Lilly and Company [Pressemappe]
Tokyo and Indianapolis (ots/PRNewswire) - Results from a health economic substudy of the TRITON-TIMI 38 clinical trial showed that among patients with acute coronary syndrome (ACS) managed with percutaneous coronary intervention ... Lesen Sie hier weiter...
]]> http://www.presseportal.de/pm/17573/1539779/eli_lilly_and_company/rss Wirtschaft Tue, 05 Jan 2010 15:47:00 +0200 redaktion@presseportal.de Eli Lilly and Company Efient(R) Exhibited Greater Antiplatelet Activity than High Dose Clopidogrel in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease http://www.presseportal.de/pm/17573/1512435/eli_lilly_and_company/rss Eli Lilly and Company: Orlando, Florida, November 15 (ots/PRNewswire) - Results from a new study showed patients with type 2 diabetes mellitus who also had coronary artery disease (CAD) and received a 60 mg loading dose and 10 mg maintenance dose of ... Eli Lilly and Company [Pressemappe]
Orlando, Florida, November 15 (ots/PRNewswire) - Results from a new study showed patients with type 2 diabetes mellitus who also had coronary artery disease (CAD) and received a 60 mg loading dose and 10 mg maintenance dose of ... Lesen Sie hier weiter...
]]> http://www.presseportal.de/pm/17573/1512435/eli_lilly_and_company/rss Finanzen Sun, 15 Nov 2009 21:05:00 +0200 redaktion@presseportal.de Eli Lilly and Company Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor http://www.presseportal.de/pm/17573/1511853/eli_lilly_and_company/rss Eli Lilly and Company: Indianapolis, November 13 (ots/PRNewswire) - Eli Lilly and Company (NYSE: LLY) announced today that Steven M. Paul, M.D., executive vice president, science and technology, and president, Lilly Research Laboratories, will retire from ... Eli Lilly and Company [Pressemappe]
Indianapolis, November 13 (ots/PRNewswire) - Eli Lilly and Company (NYSE: LLY) announced today that Steven M. Paul, M.D., executive vice president, science and technology, and president, Lilly Research Laboratories, will retire from ... Lesen Sie hier weiter...
]]> http://www.presseportal.de/pm/17573/1511853/eli_lilly_and_company/rss Finanzen Fri, 13 Nov 2009 15:10:00 +0200 redaktion@presseportal.de Eli Lilly and Company Three European Analyses Showed Efient is Cost-Effective Compared with Clopidogrel in Patients with Acute Coronary Syndrome Undergoing PCI http://www.presseportal.de/pm/17573/1499419/eli_lilly_and_company/rss Eli Lilly and Company: Paris (ots/PRNewswire) - Results from three separate European health economic analyses of the TRITON-TIMI 38 study showed that treatment with Efient(R) (prasugrel) compared with clopidogrel (Plavix(R)) reduced medical costs by ... Eli Lilly and Company [Pressemappe]
Paris (ots/PRNewswire) - Results from three separate European health economic analyses of the TRITON-TIMI 38 study showed that treatment with Efient(R) (prasugrel) compared with clopidogrel (Plavix(R)) reduced medical costs by ... Lesen Sie hier weiter...
]]> http://www.presseportal.de/pm/17573/1499419/eli_lilly_and_company/rss Wirtschaft Mon, 26 Oct 2009 08:07:00 +0200 redaktion@presseportal.de Eli Lilly and Company /C O R R E C T I O N -- Eli Lilly and Company/ http://www.presseportal.de/pm/17573/1474016/eli_lilly_and_company/rss Eli Lilly and Company: Indianapolis and Ingelheim, Germany (ots/PRNewswire) - In the news release, "New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Duloxetine" issued on 11 Sep 2009 10:00 GMT, by Eli Lilly and Company ... Eli Lilly and Company [Pressemappe]
Indianapolis and Ingelheim, Germany (ots/PRNewswire) - In the news release, "New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Duloxetine" issued on 11 Sep 2009 10:00 GMT, by Eli Lilly and Company ... Lesen Sie hier weiter...
]]> http://www.presseportal.de/pm/17573/1474016/eli_lilly_and_company/rss Finanzen Fri, 11 Sep 2009 17:57:00 +0200 redaktion@presseportal.de Eli Lilly and Company New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Duloxetine http://www.presseportal.de/pm/17573/1473685/eli_lilly_and_company/rss Eli Lilly and Company: Indianapolis and Ingelheim, Germany (ots/PRNewswire) - - Further Pain Reduction on Duloxetine Shown During Study's Extension Phase New data show patients with chronic low back pain on duloxetine hydrochloride (Cymbalta(R)) ... Eli Lilly and Company [Pressemappe]
Indianapolis and Ingelheim, Germany (ots/PRNewswire) - - Further Pain Reduction on Duloxetine Shown During Study's Extension Phase New data show patients with chronic low back pain on duloxetine hydrochloride (Cymbalta(R)) ... Lesen Sie hier weiter...
]]> http://www.presseportal.de/pm/17573/1473685/eli_lilly_and_company/rss Finanzen Fri, 11 Sep 2009 12:05:00 +0200 redaktion@presseportal.de Eli Lilly and Company Eight out of 10 People Diagnosed With Heart Disease Consider Their Diagnosis a 'Wake-Up Call' http://www.presseportal.de/pm/17573/1467038/eli_lilly_and_company/rss Eli Lilly and Company: Barcelona, Spain (ots/PRNewswire) - - Your Heart: New Start initiative launched to provide heart patients and their carers with information about nutrition, fitness and medication adherence Eight out of 10 heart patients in an ... Eli Lilly and Company [Pressemappe]
Barcelona, Spain (ots/PRNewswire) - - Your Heart: New Start initiative launched to provide heart patients and their carers with information about nutrition, fitness and medication adherence Eight out of 10 heart patients in an ... Lesen Sie hier weiter...
]]> http://www.presseportal.de/pm/17573/1467038/eli_lilly_and_company/rss Wirtschaft Mon, 31 Aug 2009 16:35:00 +0200 redaktion@presseportal.de Eli Lilly and Company World Heart Federation, Daiichi Sankyo and Lilly Partner to Improve Cardiovascular Health http://www.presseportal.de/pm/17573/1379255/eli_lilly_and_company/rss Eli Lilly and Company: Orlando, Florida (ots/PRNewswire) - The World Heart Federation, Daiichi Sankyo Company, Limited (TSE: 4568) and Eli Lilly and Company (NYSE: LLY) announced today that they have partnered to improve cardiovascular health ... Eli Lilly and Company [Pressemappe]
Orlando, Florida (ots/PRNewswire) - The World Heart Federation, Daiichi Sankyo Company, Limited (TSE: 4568) and Eli Lilly and Company (NYSE: LLY) announced today that they have partnered to improve cardiovascular health ... Lesen Sie hier weiter...
]]> http://www.presseportal.de/pm/17573/1379255/eli_lilly_and_company/rss Wirtschaft Tue, 31 Mar 2009 06:06:00 +0200 redaktion@presseportal.de Eli Lilly and Company Duloxetine Significantly Reduced Osteoarthritis Knee Pain in New Study http://www.presseportal.de/pm/17573/1344349/eli_lilly_and_company/rss Eli Lilly and Company: Indianapolis, U.s.a. and Ingelheim, Germany (ots/PRNewswire) -- - Patients on Treatment Also Experienced Improved Physical Functioning In a new study, duloxetine hydrochloride (Cymbalta(R)), administered at 60 mg to 120 mg ... Eli Lilly and Company [Pressemappe]
Indianapolis, U.s.a. and Ingelheim, Germany (ots/PRNewswire) -- - Patients on Treatment Also Experienced Improved Physical Functioning In a new study, duloxetine hydrochloride (Cymbalta(R)), administered at 60 mg to 120 mg ... Lesen Sie hier weiter...
]]> http://www.presseportal.de/pm/17573/1344349/eli_lilly_and_company/rss Finanzen Fri, 30 Jan 2009 12:05:00 +0200 redaktion@presseportal.de Eli Lilly and Company New Data Show Duloxetine Maintained Pain Reduction for More Than Six Months in Patients With Diabetic Peripheral Neuropathic Pain http://www.presseportal.de/pm/17573/1249310/eli_lilly_and_company/rss Eli Lilly and Company: Indianapolis (ots/PRNewswire) - - Study with duloxetine evaluating long-term pain reduction in treatment of DPNP is first to exceed three months Duloxetine hydrochloride maintained pain reduction in the treatment of diabetic ... Eli Lilly and Company [Pressemappe]
Indianapolis (ots/PRNewswire) - - Study with duloxetine evaluating long-term pain reduction in treatment of DPNP is first to exceed three months Duloxetine hydrochloride maintained pain reduction in the treatment of diabetic ... Lesen Sie hier weiter...
]]> http://www.presseportal.de/pm/17573/1249310/eli_lilly_and_company/rss Wirtschaft Tue, 19 Aug 2008 16:19:00 +0200 redaktion@presseportal.de Eli Lilly and Company Phase II Data on Lilly's Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimer's Disease http://www.presseportal.de/pm/17573/1237972/eli_lilly_and_company/rss Eli Lilly and Company: Chicago (ots/PRNewswire) - - Findings lead to decision to start Phase III pivotal study of LY2062430 in 2009 Eli Lilly and Company (NYSE: LLY) today announced interim results of its Phase II study of LY2062430, an ... Eli Lilly and Company [Pressemappe]
Chicago (ots/PRNewswire) - - Findings lead to decision to start Phase III pivotal study of LY2062430 in 2009 Eli Lilly and Company (NYSE: LLY) today announced interim results of its Phase II study of LY2062430, an ... Lesen Sie hier weiter...
]]> http://www.presseportal.de/pm/17573/1237972/eli_lilly_and_company/rss Finanzen Wed, 30 Jul 2008 22:21:00 +0200 redaktion@presseportal.de Eli Lilly and Company Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease http://www.presseportal.de/pm/17573/1162947/eli_lilly_and_company/rss Eli Lilly and Company: Indianapolis (ots/PRNewswire) - - Late-stage IDENTITY study of once-daily, oral agent is now enrolling patients Eli Lilly and Company (NYSE: LLY) has announced today the start of a Phase III clinical trial studying LY450139, an ... Eli Lilly and Company [Pressemappe]
Indianapolis (ots/PRNewswire) - - Late-stage IDENTITY study of once-daily, oral agent is now enrolling patients Eli Lilly and Company (NYSE: LLY) has announced today the start of a Phase III clinical trial studying LY450139, an ... Lesen Sie hier weiter...
]]> http://www.presseportal.de/pm/17573/1162947/eli_lilly_and_company/rss Wirtschaft Mon, 31 Mar 2008 10:02:00 +0200 redaktion@presseportal.de Eli Lilly and Company Lilly gibt Weltgesundheitsorganisation 4,4 Mio. US-Dollar für Ausbau von MDR-TB-Programm http://www.presseportal.de/pm/17573/1152742/eli_lilly_and_company/rss Eli Lilly and Company: Indianapolis und London (ots/PRNewswire) - Eli Lilly and Company kündigte heute die Vergabe von Forschungsgeldern in Höhe von 4.384.000 USD an die Weltgesundheitsorganisation (WHO) an. Diese Fördermittel sollen über die nächsten vier ... Eli Lilly and Company [Pressemappe]
Indianapolis und London (ots/PRNewswire) - Eli Lilly and Company kündigte heute die Vergabe von Forschungsgeldern in Höhe von 4.384.000 USD an die Weltgesundheitsorganisation (WHO) an. Diese Fördermittel sollen über die nächsten vier ... Lesen Sie hier weiter...
]]> http://www.presseportal.de/pm/17573/1152742/eli_lilly_and_company/rss Wirtschaft Wed, 12 Mar 2008 09:06:00 +0200 redaktion@presseportal.de Eli Lilly and Company FORSTEO(R) erhält positive Einschätzung des Europäischen Ausschusses für Humanarzneimittel (CHMP) zur Behandlung von glukokortikoidinduzierter Osteoporose http://www.presseportal.de/pm/17573/1141243/eli_lilly_and_company/rss Eli Lilly and Company: Indianapolis (ots/PRNewswire) - - Im Falle der Zulassung stände der knochenbildende Wirkstoff für Osteoporose einer neuen Patientenpopulation zur Verfügung Eli Lilly and Company (NYSE: LLY) meldete heute, dass der Ausschuss für ... Eli Lilly and Company [Pressemappe]
Indianapolis (ots/PRNewswire) - - Im Falle der Zulassung stände der knochenbildende Wirkstoff für Osteoporose einer neuen Patientenpopulation zur Verfügung Eli Lilly and Company (NYSE: LLY) meldete heute, dass der Ausschuss für ... Lesen Sie hier weiter...
]]> http://www.presseportal.de/pm/17573/1141243/eli_lilly_and_company/rss Wirtschaft Sat, 23 Feb 2008 00:00:00 +0200 redaktion@presseportal.de Eli Lilly and Company Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase III Study Against Clopidogrel http://www.presseportal.de/pm/17573/1077294/eli_lilly_and_company/rss Eli Lilly and Company: Tokyo and Indianapolis, November 4 (ots/PRNewswire) - - Duke Clinical Research Institute to lead multinational study with investigational compound; will include 10,000 medically managed patients with acute coronary syndrome A large Phase ... Eli Lilly and Company [Pressemappe]
Tokyo and Indianapolis, November 4 (ots/PRNewswire) - - Duke Clinical Research Institute to lead multinational study with investigational compound; will include 10,000 medically managed patients with acute coronary syndrome A large Phase ... Lesen Sie hier weiter...
]]> http://www.presseportal.de/pm/17573/1077294/eli_lilly_and_company/rss Wirtschaft Sun, 04 Nov 2007 14:08:00 +0200 redaktion@presseportal.de Eli Lilly and Company